Clinical Trials Browser

Phase 1/2 × INDUSTRY × vadastuximab talirine × Clear all

NCT02614560 2019-01-09

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Phase 1/2 Terminated

14 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute